Form 4: Edesa Biotech CEO Pardeep Nijhawan Reports Acquisition of Fully Vested Restricted Share Units

Edesa Biotech's Chief Executive Officer, Pardeep Nijhawan, reported the acquisition of 7,186 fully vested common shares through a restricted share unit grant, increasing his total beneficial ownership to 916,381 shares.

Summary

• Pardeep Nijhawan, Edesa Biotech's Director, 10% Owner, and Chief Executive Officer, acquired 7,186 common shares on July 2, 2025.
• The acquisition was a grant of restricted share units (RSUs) under the Issuer's 2019 Equity Incentive Compensation Plan.
• The RSUs vested in full upon grant, with a reported price of $0 per share.
• Following this transaction, Pardeep Nijhawan's direct beneficial ownership stands at 456,953 common shares.
• Indirect beneficial ownership includes 341,702 common shares held by Pardeep Nijhawan Medicine Professional Corporation, 32,609 by The New Nijhawan Family Trust 2015, 32,013 by The Digestive Health Clinic Inc., and 53,104 by 1968160 Ontario Inc.
• The total beneficial ownership, including direct and indirect holdings, amounts to 916,381 common shares.

Sentiment

Score: 7

Explanation: The grant of fully vested restricted share units to the CEO is a positive event, aligning management's interests with shareholders and indicating continued commitment. While not a direct financial performance indicator, it reflects a positive aspect of corporate governance and executive compensation.

Positives

• The grant of 7,186 restricted share units to the CEO, Pardeep Nijhawan, aligns management's interests with shareholders.
• The RSUs vested immediately upon grant, indicating a direct increase in the CEO's equity stake.
• The transaction was made pursuant to a Rule 10b5-1 plan, demonstrating a pre-arranged and compliant equity acquisition.

Future Outlook

NA

Industry Context

This Form 4 filing reflects a routine insider transaction related to executive compensation, common across various industries where equity grants are used to incentivize and align management with company performance. It does not provide broader industry trends or competitive insights.

Related Party Transactions

• Pardeep Nijhawan's indirect beneficial ownership includes shares held by entities wholly-owned by him (Pardeep Nijhawan Medicine Professional Corporation, The Digestive Health Clinic Inc., 1968160 Ontario Inc.) and a trust where he is a co-trustee (The New Nijhawan Family Trust 2015). The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: The grant of RSUs to the CEO can be seen as a positive for shareholders as it further aligns the CEO's financial interests with the company's performance, potentially leading to more focused leadership.
• Management (Pardeep Nijhawan): Directly benefits from an increase in equity ownership and compensation.

Key Dates

Keywords

Edesa Biotech, EDSA, Pardeep Nijhawan, SEC Form 4, Insider Transaction, Restricted Share Units, Equity Grant, Beneficial Ownership, CEO, Director, 10% Owner